

produced gradually as tolerated by the patient, Dr. Ghali said.

To achieve long-standing improvement, acne patients typically require a total isotretinoin course of 150 mg/kg. Patients with severe, sudden-onset inflammatory acne are no different and should receive at least the standard total course or sometimes even greater amounts over time if necessary, depending on the severity of the case and the patient's response.

"What if it takes 8-10 months to complete the course in some patients? So be it," Dr. Ghali said. For these severely inflamed acne patients, the main issue is en-

suring they receive an adequate cumulative course of isotretinoin, rather than attempting to complete the treatment within the 5-month treatment window that applies to most acne patients.

If the diagnosis is truly acne fulminans, arthralgia can be treated with NSAIDs. A longer course of oral prednisone may be required, he said. Again, isotretinoin should be initiated at a low dose for best results, and gradually increased over time.

Dr. Ghali reported no relevant conflicts of interest in regard to his presentation.

SDEF and this news organization are owned by Elsevier. ■



COURTESY DR. FRED GHALI

**Inflamed lesions may appear explosively, as on the chest of this teenage boy. Lesions are usually tender and bleed.**

## Dapsone Gel Can Now Be Used for Acne

LAS VEGAS — After years of delay, topical dapsone gel 5% can now be prescribed for patients with mild to moderate acne, marking the first new chemically based drug treatment for acne in a decade.

A sulfone drug, Aczone 5% gel has anti-inflammatory and antimicrobial properties. "It's a drug we know well from dermatitis herpetiformis and other diseases," said Dr. Guy Webster at a dermatology seminar sponsored by Skin Disease Education Foundation.

However, the topical gel form appears to be much safer, free from the hemolysis, hemolytic anemia, and peripheral neuropathy that can result from oral administration of the drug for Hansen's disease or serious skin disorders, said Dr. Webster, a dermatologist in private practice in Hockessin, Del.

No blood tests will be required for patients receiving topical dapsone, based on an FDA revision of drug labeling for the product last March.

In clinical trials involving more than 3,000 patients, the inflammatory lesion count among patients receiving active dapsone gel declined 24% within 2 weeks.

The total lesion count declined 48% in patients receiving dapsone gel by week 12, a statistically superior result to the 42% lesion count reduction seen in patients who received the vehicle alone.

Side effects were mostly mild and similar to the profile seen with other topical acne products. They included erythema, dryness, oiliness, and peeling. "This is going to be a very, very safe drug, very well tolerated," Dr. Webster said.

He predicted the gel will be prescribed as a first-line treatment for patients with mild to moderate acne but said it remains to be seen whether topical dapsone will ultimately play a role in treating patients with severe acne, either alone or in combination with other drugs.

"My suspicion is that at the very least, it will be competitive with clindamycin monotherapy or benzoyl peroxide monotherapy," he said.


Dr. Webster disclosed that he is a consultant to Allergan.

SDEF and this news organization are wholly owned subsidiaries of Elsevier.

—Betsy Bates

For patients with hypertension

Take control with POWER and LASTING BP PROTECTION



#1  
THE FASTEST GROWING ARB™

#### USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, MICARDIS Tablets should be discontinued as soon as possible (see WARNINGS, Fetal/Neonatal Morbidity and Mortality).

MICARDIS is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

MICARDIS is contraindicated in patients who are hypersensitive to any component of this product. The most common adverse events occurring with MICARDIS Tablets monotherapy at a rate of  $\geq 1\%$  and greater than placebo, respectively, were: upper respiratory tract infection (URTI) (7%, 6%), back pain (3%, 1%), sinusitis (3%, 2%), diarrhea (3%, 2%), and pharyngitis (1%, 0%).

\*Source: IMS Health. Year-to-year comparison of NRxs and TRxs for MICARDIS across all specialties.

Reference: 1. IMS HEALTH, IMS National Prescription Audit™, January 2007 to December 2008.

Please see Brief Summary of Product Information on adjacent page.

For full Prescribing Information, including boxed WARNING, please see [www.MICARDIS.com](http://www.MICARDIS.com). For additional information about hypertension, please visit [www.BPProtection.com](http://www.BPProtection.com).



**MICARDIS**  
Telmisartan Tablets

POWER and LASTING BP PROTECTION